How Flex Databases’ Review and Merge Tool Transforms Pharmacovigilance Case Processing

Case intake is rarely a single channel – it’s a convergence of several:

• EDC systems from clinical trials – when a patient experiences an adverse event on an investigational product, the investigator reports it, and the case flows into the PV system.

• Client relation forms for marketed drugs – any consumer can report an adverse event directly through a pharma company’s website.

• Partners and regulatory authorities – cases can arrive as structured XML imports, for example when a doctor or consumer reports an event to a regulatory authority and the sponsor imports that data, or when an international partner relays safety data back.

Each of these channels can generate not just a new case, but repeated updates to an existing case — sometimes dozens of them for a single ADR or serious case.

The Review and Merge Tool addresses this at the source – by treating an incoming update not as a replacement, but as a delta to be reconciled against existing work.

• Faster turnaround on regulatory reporting timelines, since specialists spend less time reconstructing context and more time on substantive review.

• Reduced risk of lost clinical judgment, since prior causality assessments and coding decisions no longer disappear when a new version arrives.

• More consistent audit trails, since every update – however it entered the system – gets properly classified and traced.

• Scalable case management, since teams handling high-volume products or serious cases with many follow-ups aren’t penalized with linearly increasing manual effort per version.